BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34330779)

  • 21. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
    Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
    Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.
    Benight NM; Wagh PK; Zinser GM; Peace BE; Stuart WD; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE
    Oncotarget; 2015 Jul; 6(19):17445-61. PubMed ID: 25938541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the Short Form of RON/STK in Feline Mammary Carcinoma.
    Maniscalco L; Guil-Luna S; Iussich S; Gattino F; Trupia C; Millan Y; de Las Mulas JM; Cespedez RS; Saeki K; Accornero P; De Maria R
    Vet Pathol; 2019 Mar; 56(2):220-229. PubMed ID: 30558510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
    Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
    Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
    Guin S; Yao HP; Wang MH
    Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.
    Sharma S; Zeng JY; Zhuang CM; Zhou YQ; Yao HP; Hu X; Zhang R; Wang MH
    Mol Cancer Ther; 2013 May; 12(5):725-36. PubMed ID: 23468529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.
    Kretschmann KL; Eyob H; Buys SS; Welm AL
    Curr Drug Targets; 2010 Sep; 11(9):1157-68. PubMed ID: 20545605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer.
    Peace BE; Toney-Earley K; Collins MH; Waltz SE
    Cancer Res; 2005 Feb; 65(4):1285-93. PubMed ID: 15735014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
    Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
    Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.
    Kato A; Ng S; Thangasamy A; Han H; Zhou W; Raeppel S; Fallon M; Guha S; Ammanamanchi S
    Mol Carcinog; 2021 Nov; 60(11):734-745. PubMed ID: 34347914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential.
    Faham N; Zhao L; Welm AL
    NPJ Breast Cancer; 2018; 4():36. PubMed ID: 30456298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.
    Lee WY; Chen HH; Chow NH; Su WC; Lin PW; Guo HR
    Clin Cancer Res; 2005 Mar; 11(6):2222-8. PubMed ID: 15788670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence.
    Hunt BG; Davis JC; Fox LH; Vicente-Muñoz S; Lester C; Wells SI; Waltz SE
    Oncogene; 2023 May; 42(21):1716-1727. PubMed ID: 37029299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
    Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
    Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
    Liu J; Blake SJ; Yong MC; Harjunpää H; Ngiow SF; Takeda K; Young A; O'Donnell JS; Allen S; Smyth MJ; Teng MW
    Cancer Discov; 2016 Dec; 6(12):1382-1399. PubMed ID: 27663893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.
    Chakedis J; French R; Babicky M; Jaquish D; Mose E; Cheng P; Holman P; Howard H; Miyamoto J; Porras P; Walterscheid Z; Schultz-Fademrecht C; Esdar C; Schadt O; Eickhoff J; Lowy AM
    Oncotarget; 2016 Jul; 7(29):45959-45975. PubMed ID: 27323855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.